Last reviewed · How we verify
pyrimethamine-sulfadiazine + prednisolone
pyrimethamine-sulfadiazine + prednisolone is a Antiparasitic agent + corticosteroid combination Small molecule drug developed by Shahid Beheshti University of Medical Sciences. It is currently in Phase 3 development for Toxoplasmosis with inflammatory complications, Parasitic infections requiring immunosuppressive management.
This combination uses pyrimethamine and sulfadiazine as antimicrobial agents to treat parasitic or protozoal infections, while prednisolone provides immunosuppression and anti-inflammatory effects.
This combination uses pyrimethamine and sulfadiazine as antimicrobial agents to treat parasitic or protozoal infections, while prednisolone provides immunosuppression and anti-inflammatory effects. Used for Toxoplasmosis with inflammatory complications, Parasitic infections requiring immunosuppressive management.
At a glance
| Generic name | pyrimethamine-sulfadiazine + prednisolone |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Antiparasitic agent + corticosteroid combination |
| Target | Dihydrofolate reductase (pyrimethamine); folate synthesis pathway (sulfadiazine); glucocorticoid receptor (prednisolone) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Pyrimethamine and sulfadiazine work synergistically to inhibit folate metabolism in parasites (particularly Toxoplasma gondii), disrupting nucleotide synthesis and parasite replication. Prednisolone, a corticosteroid, reduces inflammation and modulates immune responses, potentially preventing immune-mediated complications. This combination is typically used in conditions where parasitic infection triggers significant inflammatory pathology.
Approved indications
- Toxoplasmosis with inflammatory complications
- Parasitic infections requiring immunosuppressive management
Common side effects
- Bone marrow suppression
- Rash / Stevens-Johnson syndrome risk
- Immunosuppression-related infections
- Gastrointestinal disturbance
- Corticosteroid-related adverse effects (hyperglycemia, osteoporosis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pyrimethamine-sulfadiazine + prednisolone CI brief — competitive landscape report
- pyrimethamine-sulfadiazine + prednisolone updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI
Frequently asked questions about pyrimethamine-sulfadiazine + prednisolone
What is pyrimethamine-sulfadiazine + prednisolone?
How does pyrimethamine-sulfadiazine + prednisolone work?
What is pyrimethamine-sulfadiazine + prednisolone used for?
Who makes pyrimethamine-sulfadiazine + prednisolone?
What drug class is pyrimethamine-sulfadiazine + prednisolone in?
What development phase is pyrimethamine-sulfadiazine + prednisolone in?
What are the side effects of pyrimethamine-sulfadiazine + prednisolone?
What does pyrimethamine-sulfadiazine + prednisolone target?
Related
- Drug class: All Antiparasitic agent + corticosteroid combination drugs
- Target: All drugs targeting Dihydrofolate reductase (pyrimethamine); folate synthesis pathway (sulfadiazine); glucocorticoid receptor (prednisolone)
- Manufacturer: Shahid Beheshti University of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Toxoplasmosis with inflammatory complications
- Indication: Drugs for Parasitic infections requiring immunosuppressive management
- Compare: pyrimethamine-sulfadiazine + prednisolone vs similar drugs
- Pricing: pyrimethamine-sulfadiazine + prednisolone cost, discount & access